Compass Therapeutics (NASDAQ:CMPX) Rating Lowered to “Sell” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other research firms have also recently commented on CMPX. Jefferies Financial Group restated a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a research report on Thursday, March 5th. Cantor Fitzgerald restated an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. William Blair restated an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Raymond James Financial restated an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $13.11.

Compass Therapeutics Trading Down 3.8%

NASDAQ CMPX opened at $5.01 on Friday. Compass Therapeutics has a 52 week low of $1.66 and a 52 week high of $6.88. The stock has a market cap of $902.78 million, a price-to-earnings ratio of -11.66 and a beta of 1.49. The company has a 50-day moving average price of $5.55 and a two-hundred day moving average price of $5.28.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Thursday, March 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.01. As a group, equities research analysts expect that Compass Therapeutics will post -0.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Suvretta Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 0.6% in the fourth quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company’s stock valued at $76,159,000 after acquiring an additional 81,220 shares in the last quarter. Vivo Capital LLC boosted its holdings in shares of Compass Therapeutics by 57.9% in the third quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock valued at $33,409,000 after acquiring an additional 3,502,000 shares in the last quarter. BVF Inc. IL boosted its holdings in shares of Compass Therapeutics by 63.5% in the fourth quarter. BVF Inc. IL now owns 7,764,842 shares of the company’s stock valued at $41,697,000 after acquiring an additional 3,014,842 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Compass Therapeutics by 45.6% in the third quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock valued at $24,720,000 after acquiring an additional 2,212,794 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Compass Therapeutics by 57.4% in the fourth quarter. State Street Corp now owns 4,890,525 shares of the company’s stock valued at $26,262,000 after acquiring an additional 1,784,012 shares in the last quarter. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.